Combined treatment with DPP-4 inhibitor linagliptin and SGLT2 inhibitor empagliflozin attenuates neointima formation after vascular injury in diabetic mice

Combined treatment with DPP-4 inhibitor linagliptin and SGLT2 inhibitor empagliflozin attenuates neointima formation after vascular injury in diabetic mice

Incretin therapy has emerged as one of the most popular medications for type 2 diabetes. We have previously reported that the dipeptidyl peptidase-4 (DPP-4) inhibitor linagliptin attenuates neointima formation after vascular injury in non-diabetic mice. In the present study, we examined whether comb...

Full description

Bibliographic Details
Main Authors: Hiroyuki Takahashi, Takashi Nomiyama, Yuichi Terawaki, Takeshi Horikawa, Takako Kawanami, Yuriko Hamaguchi, Tomoko Tanaka, Ryoko Motonaga, Takashi Fukuda, Makito Tanabe, Toshihiko Yanase
Format: Article
Language:English
Published: Elsevier 2019-07-01
Series:Biochemistry and Biophysics Reports
Online Access:http://www.sciencedirect.com/science/article/pii/S2405580818302668

Internet

http://www.sciencedirect.com/science/article/pii/S2405580818302668

Similar Items